Research into which therapeutic effects are obtained by blocking inflammation and tissue damage through CCL2–CCR2 is being conducted for various diseases, such as rheumatoid arthritis (RA), cancer, atherosclerosis, myocardial infarction, and OA [7–10]. This evidence concerns the gene CCR2 and myocardial infarction.